MET-233I
A Study of MET233 in Individuals With Obesity or Overweight
Pfizer · Phase 1 · Completed · Enrollment 144
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| (Part A) MET233 | n/r | n/r | n/r | n/r | n/r |
| (Part A) Placebo | n/r | n/r | n/r | n/r | n/r |
| (Part B) MET233 | n/r | n/r | n/r | n/r | n/r |
| (Part B) Placebo | n/r | n/r | n/r | n/r | n/r |
| (Part C) MET233 | n/r | n/r | n/r | n/r | n/r |
| (Part C) Placebo | n/r | n/r | n/r | n/r | n/r |
| (Part D) MET233 | n/r | n/r | n/r | n/r | n/r |
| (Part D) Placebo | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.